Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Cash & Equivalents (2017 - 2025)

Q32 Bio (QTTB) has 9 years of Cash & Equivalents data on record, last reported at $48.3 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 38.05% year-over-year to $48.3 million; the TTM value through Dec 2025 reached $48.3 million, down 38.05%, while the annual FY2025 figure was $48.3 million, 38.05% down from the prior year.
  • Cash & Equivalents reached $48.3 million in Q4 2025 per QTTB's latest filing, down from $49.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $248.1 million in Q1 2022 and bottomed at $20.1 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $82.1 million, with a median of $71.7 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: tumbled 88.62% in 2023, then surged 386.94% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $110.3 million in 2021, then crashed by 69.2% to $34.0 million in 2022, then fell by 24.62% to $25.6 million in 2023, then surged by 204.35% to $78.0 million in 2024, then plummeted by 38.05% to $48.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $48.3 million in Q4 2025, $49.0 million in Q3 2025, and $54.8 million in Q2 2025.